Serum macrophage colony-stimulating factor (M-CSF) levels correlate with clinical response to interferon-alpha in patients with early-stage B-CLL.
Interferon-alpha (IFN-alpha) reduces peripheral lymphocyte counts in B-CLL (CLL). In eight patients with stage 0 CLL on IFN-alpha therapy, peripheral lymphocyte counts fell to 61.7 +/- 19.5% of baseline at week 2 (P < 0.01), while serum M-CSF levels rose from 455 +/- 183 U/ml to 686 +/- 110 U/ml (P < 0.05). Neopterin levels also showed a significant rise. M-CSF levels were correlated with clinical response in these patients. Increased production of M-CSF and the activation of mononuclear phagocytes may be involved in clinical responses to IFN-alpha in early-stage CLL.
Jewell
A P
AP
Department of Haematology, University College, Middlesex School of Medicine, London.
Yong
K L
KL
Worman
C P
CP
Tsakona
C P
CP
Giles
F J
FJ
Goldstone
A H
AH
D001708:Biopterins / Q000031:analogs & derivatives / Q000097:blood; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000097:blood* / Q000628:therapy; D007958:Leukocyte Count; D008214:Lymphocytes / Q000473:pathology; D016173:Macrophage Colony-Stimulating Factor / Q000097:blood*; D019798:Neopterin; D011994:Recombinant Proteins
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D001708:Biopterins; D019798:Neopterin; D016173:Macrophage Colony-Stimulating Factor